Entrada Q3 net loss $14.0M; advancing DMD franchise with regulatory filings on track

Entrada Therapeutics, Inc.

2024-Q3 EPS reported $1.72 revenue$173,384,000

Net loss $14.0M in Q3 2024 (vs $35.5M net income in Q3 2023); revenue down to $19.6M from $43.7M.
Cash $449.3M as of Sep 30, 2024, up from $352.0M at end of 2023; funded by $100M offering and $75M milestone.
R&D expenses $31.3M (vs $22.2M) driven by DMD candidates; G&A $10.0M (vs $7.5M).
On track to submit global regulatory filings for Phase 2 trials of ENTR-601-44 and ENTR-601-45 in Q4 2024.
Vertex completed SAD and initiated MAD for VX-670 in DM1; Sethuraman promoted to President of R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.